Q1 2017 Results

Regulatory News Service

27 April 2017 at 07:00

Thursday, 27 April 2017

Pascal Soriot, Chief Executive Officer, commenting on the results said:

“Our good start to the year supported our guidance for 2017. Notably, Emerging Markets became our largest region, representing 32% of sales. The pipeline continued to deliver in what we expect will be a pivotal year for AstraZeneca as we announced important developments, in particular in Oncology. In addition to the availability of positive data for Lynparza in ovarian and breast cancer, we also received full approvals in the US and Europe for Tagrisso in lung cancer and launched this important medicine in record time in China. While we were disappointed to receive the Complete Response Letter for ZS-9, we remain confident in this treatment for hyperkalaemia.

“The Total Revenue performance reflected the transitional impact of recent patent expiries, which is expected to recede in the second half of the year. Importantly, we anticipate the significant progress of the pipeline to continue, including our Immuno-Oncology and targeted treatments. We will also maintain our commitment to drive efficiency across the company to support our efforts to bring new medicines to patients.”


Q1 2017 Results announcement (PDF 1.2mb)

Q1 2017 Results presentation (PDF 5.8mb)

Q1 2017 Results Clinical trials appendix (PDF 2.1mb)

Q1 2017 Results Transcript (PDF 1mb)


  • Regulatory